📣 Calling dermatology residents & rheumatology fellows! Elevate your expertise in psoriasis & psoriatic arthritis at the 2024 Dermatology Residents' and Rheumatology Fellows' Meeting in Salt Lake City, on Oct 19-20. Apply today: psoriasis.org/residents-meet…

🩺🔬Also today at IDEOM: Dr. Hassan Hamade (Mt. Sinai) presented on the PEST screener and PsAID-12 (PsA Impact of Disease). These tools facilitate conversations among dermatologists and rheumatologists when considering PsA. The goal? Empowering doctors to better manage PsA.

Today at IDEOM in D.C., we heard from Dr. April Armstrong sharing her NPF collaborations, which shed light on patient satisfaction. Understanding patient perspectives is crucial for developing effective therapies that go beyond clinical definitions of health.

Insights from our annual survey reveal that even when #psoriasis patients achieve low body surface area involvement, nearly half don't perceive their disease in remission. Join us at SID to discuss this vital research and its implications for treatment strategies.

Didn't get to catch all the posters at #AAD2024 ? Our latest article delves into groundbreaking research on psoriasis comorbidities, mental health impacts, and treatment efficacy. Visit our website to explore the full insights: psoriasis.org/advance/psoria…

Congratulations to all the #AAD2024elections winners, including our Director, Dr. Larry Green! We're looking forward to working together with these esteemed professionals to advance dermatology and improve the lives of those affected by #psoriasis and #psoriaticarthritis .

Congratulations to the recipients of the 2024 NPF Medical Professional Awards. These individuals exemplify excellence in advancing psoriatic disease care. Thank you for your dedication to improving lives through research, treatment, and education. psoriasis.org/medical-profes…

SPEVIGO® is now approved to treat Generalized Pustular Psoriasis in adults and children aged 12 and above. This expanded approval addresses the need for acute and chronic treatment for GPP patients.

Learn more ➡️ psoriasis.org/advance/fda-sp…

NPF medical board chair, Dr. Andrew Blauvelt, presented results from his 'knockout study' at #AAD2024 . Results show patients who received a high induction dose of risankizumab at weeks 0, 4,& 16 experienced sustained response through 52 weeks, with no further treatment required.

Joel Gelfand, MD, MSCE and colleagues presented the Light Treatment Effectiveness Study at the American Academy of Dermatology Annual Meeting, revealing effectiveness of home phototherapy for psoriasis treatment.

bit.ly/3PdR61i
Joel M Gelfand MD MSCE FAAD National Psoriasis Foundation AAD

Dr Richard Langley reminded us that the consequence of psoriatic disease should demand early attention. The “risk of not treating is both a matter of quality of life but also quantity of life.” #AAD2024

#DYK NPF has a seal of recognition highlighting non-irritating, safe over-the-counter products for psoriatic disease and sensitive skin? 🔗psoriasis.org/seal-of-recogn…

Fascinating results from National Psoriasis Foundation Medical Board Chair Dr. Andrew Blauvelt presented at #AAD2024 . Durable clearance is being achieved with high dose risankizumab. 83% achieved a PASI 100 and half remained clear at 52 weeks.

Thanks for a great LITE Study report at #AAD2024 . Read the breaking at home light therapy news from National Psoriasis Foundation, Penn Medicine, and University of Utah world.einnews.com/pr_news/694327…